semaglutide fda submission approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease 📢 FDA has determined the

As a GLP-1, GIP, and GCG tri-agonist, it mimics natural hormones that regulate hunger and blood sugar, offering a robust weight loss method

Searches for Retatrutide, an experimental weight loss drug currently undergoing clinical trials but being freely sold online, increased by 900 per cent

However, a reduction in cardiovascular risk has only been demonstrated thus far in cardiovascular outcome trials specifically designed in patients with obesity for semaglutide, whereas naltrexone plus bupropion did not show significant cardiovascular benefits

Contact the compounding pharmacy directly if you can identify which one filled your prescription